Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Synergistic effects of MALT1 inhibitor and selinexor on Acute Myeloid Leukemia cells and the underlying mechanisms

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZhenzhen Wang

Discussion

Loading...

Member takes

Overview

Combination therapy enhances apoptosis in AML through Bcl-xL downregulation, suggesting a novel treatment strategy.

Key Points

  • This research examines the combined effects of a MALT1 inhibitor and selinexor on apoptosis in Acute Myeloid Leukemia cells.
  • Investigated MI2 and selinexor on THP-1 and MOLM-13 AML cell lines.
  • Measured cell viability using CCK-8 assay and examined apoptosis via flow cytometry.
  • Analyzed protein expression of apoptotic markers and anti-apoptotic regulators using Western blotting.
  • MI2 and selinexor independently suppressed AML cell proliferation.
  • Combined treatment showed synergistic inhibition of cell growth and increased apoptosis.
  • The combination significantly upregulated PARP-1, downregulated Bcl-xL, and affected NF-κB pathway proteins.

Cite This Study

Zhenzhen Wang (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc1dhttps://doi.org/10.1182/blood-2025-7851
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma2025
  2. 2Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia2024 · 3 citations
  3. 3Selinexor potentiates NK cell activation against multiple myeloma2026
  4. 4Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study2026
  5. 5Effects of BCL-2 and MCL-1 Inhibition on Apoptotic and Transcriptional Profiles in Acute Myeloid Leukemia2026